EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers

Nate Way, Edward Dabrowski, Mitchell Paulin, Martin Taylor, John Madden, Amandeep Mann, Jonathan Bouchard

Journal of Comparative Effectiveness Research · 2026-05 · 15 (5)

DOI: 10.57264/cer-2025-0181 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-05. Verfasst von Nate Way und 6 weiteren Autor:innen. Beteiligte Einrichtung: Real World Evidence, Cerner Enviza, an Oracle Company, Malvern, PA 19301, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Muscle Spasticity, Neuromuscular Agents, Drug Substitution. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess patient characteristics, treatment patterns, botulinum toxin type-A (BoNT-A) costs and describe safety in adults with spasticity who switched from onabotulinumtoxinA to abobotulinumtoxinA. Materials & methods: Chart data from three US-based treatment centers was collected in patients aged ≥18 years with upper limb (ULS), lower limb (LLS) or ULS and LLS (ULS + LLS) spasticity. Eligible patients had ≥2 onabotulinumtoxinA treatment cycles before switching to abobotulinumtoxinA; they were followed for three additional abobotulinumtoxinA treatment cycles. A post hoc analysis of estimated drug costs was conducted.

Results

Eighty-eight patients (mean age 44.9 years; 62.5% male) switched from onabotulinumtoxinA to abobotulinumtoxinA; in 84 (95.5%), the switch was due to ‘medical need/effectiveness not achieved.’ Most common spasticity etiologies were cerebral palsy (43.2%) and stroke (25.0%). Fifty-one patients (58.0%) had bilateral spasticity with a mean ± SD of 5.1 ± 2.2 muscles injected at each visit over the 5-injection-cycle treatment period. No adverse events were reported following switching. Mean estimated cost per visit was $2731 with onabotulinumtoxinA and $1452 with abobotulinumtoxinA.

Conclusion

In this real-world study, patients with ULS, LLS or ULS + LLS who were switched from onabotulinumtoxinA to abobotulinumtoxinA continued for ≥3 treatment cycles without any reported adverse events. Switching resulted in lower estimated BoNT-A costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AMuscle SpasticityNeuromuscular AgentsDrug SubstitutionHumansMaleAdultFemaleMiddle AgedUnited StatesRetrospective StudiesAged

Stichwörter der Autor:innen

abobotulinumtoxinAonabotulinumtoxinAreal-world studyspasticitytreatment switch

Substanzen

Botulinum Toxins, Type AabobotulinumtoxinAonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Real World Evidence, Cerner Enviza, an Oracle Company, Malvern, PA 19301, USA.
  • Beaumont Health, Royal Oak, MI 48073, USA.
  • The Center for Tone Management of the Main Line, Paoli, PA 19301, USA.
  • OrthoNeuro, New Albany, OH 43054, USA.
  • Ipsen, Cambridge, MA 02142, USA.

Zitieren

APA

Way, N., Dabrowski, E., Paulin, M., Taylor, M., Madden, J., Mann, A., & Bouchard, J. (2026). Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers. Journal of Comparative Effectiveness Research, 15(5). https://doi.org/10.57264/cer-2025-0181

Vancouver

Way N, Dabrowski E, Paulin M, Taylor M, Madden J, Mann A, et al. Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers. Journal of Comparative Effectiveness Research. 2026;15(5). doi:10.57264/cer-2025-0181

BibTeX
@article{Way2026,
  author = {Way, Nate and Dabrowski, Edward and Paulin, Mitchell and Taylor, Martin and Madden, John and Mann, Amandeep and Bouchard, Jonathan},
  title = {Switching adult patients with spasticity from onabotulinumtoxinA to abobotulinumtoxinA: a real-world data analysis across three US-based treatment centers},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2026},
  volume = {15},
  number = {5},
  doi = {10.57264/cer-2025-0181}
}
Kostenlos starten →